• 1
    Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BEC, Barrett-Connor E, Black D, Bonjour JP, Dawson-Hughes B, Delmas PD, Dequeker J, Ragi Eis S, Gennari C, Johnell O, Johnston CC, Lau EMC, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen C, Meunier PJ, Miller PD, Mithal A, Morii H, Papapoulos S, Woolf A, Yu W, Khaltaev N 2000 Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10:259264.
  • 2
    Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:12271233.
  • 3
    Melton LJ III, Atkinson EJ, Khosla S, O'Fallon WM, Riggs BL 1999 Secondary osteoporosis and the risk of vertebral deformities in women. Bone 24:4955.
  • 4
    Ross PD, Davis JW, Epstein RS, Wasnich RD 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919923.
  • 5
    Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E 2001 Risk of new vertebral fracture in the year following a fracture. JAMA 285:320323.
  • 6
    Black DM, Arden NK, Palermo L, Pearson J, Cummings SR 1999 Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821828.
  • 7
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282:637645.
  • 8
    Cummings S, Black D, Thompson DE, Applegate WB, Barrett-Connor E, Musliner T, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, for the Fracture Intervention Trial Research Group 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:20772082.
  • 9
    Lufkin EG, Wong M, Deal C 2001 The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum Dis Clin North Am 27:163185.
  • 10
    Eastell R 1998 Treatment of postmenopausal osteoporosis. N Engl J Med 338:736746.
  • 11
    Fleming TR, DeMets DL 1996 Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 125:605613.
  • 12
    Black DM, Sarkar S, Mitlak BH, Knickerbocker R, Cummings SR 1999 What proportion of the effects of raloxifene (RLX) on vertebral fracture risk can be directly attributed to its bone mineral density (BMD) effects? J Bone Miner Res 14:S158.
  • 13
    Cummings SR, Black DM, Pearson J, Karpf DB, Harris F, Genant HK, LaCroix AZ 1999 How much of the reduction in risk of vertebral fractures by alendronate is explained by increased spine BMD? J Bone Miner Res 14:S159.
  • 14
    Black DM, Pearson J, Harris F, Lacroix A, Cummings S 1999 Predicting the effect of antiresorptive treatments on risk of vertebral fractures: A meta-analysis. J Bone Miner Res 14:S137.
  • 15
    Cummings SR, Black DM, Vogt TM 1996 Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Miner Res 11:S102.
  • 16
    Watts N, Bockman R, Smith C, Li Z, Eastell R, Pack S, Lindsay R 2000 BMD changes explains only a fraction of the observed fracture risk reduction in risedronate-treated patients Osteoporos Int 11:S203.
  • 17
    McCullagh P, Nelder JA 1989 Monographs on Statistics and Applied Probability: Generalized Linear Models, 2nd ed. Chapman and Hall, London, UK.
  • 18
    Freedman LS, Graubard BI, Schatzkin A 1992 Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167178.
  • 19
    Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341:7275.
  • 20
    Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:12541259.
  • 21
    Lu Y, Mathur AK, Blunt BA, Gluer CC, Will AS, Fuerst TP, Jergas MD, Andriano KN, Cummings SR, Genant HK 1996 Dual X-ray absorptiometry quality control: Comparison of visual examination and process-control charts. J Bone Miner Res 11:626637.
  • 22
    Lu Y, Ye K, Mathur AK, Hui S, Fuerst TP, Genant HK 1997 Comparative calibration without a gold standard. Stat Med 16:18891905.
  • 23
    Burger H, van Daele PL, Algra D, van den Ouweland FA, Grobbee DE, Hofman A, van Kuijk C, Schutte HE, Birkenhager JC, Pols HA 1994 The association between age and bone mineral density in men and women aged 55 years and over: The Rotterdam Study. Bone Miner 25:113.
  • 24
    Patel R, Blake GM, Rymer J, Fogelman I 2000 Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 11:6875.
  • 25
    Haddaway MJ, Davie MW, McCall IW 1992 Bone mineral density in healthy normal women and reproducibility of measurements in spine and hip using dual-energy X-ray absorptiometry. Br J Radiol 65:213217.
  • 26
    Watts N, Sarkar S, Wu W, Wong M, Harper KD 2001 Validation of change in bone mineral density as a surrogate for fracture risk after statistical adjustment for imprecision in BMD measurements. Bone 28(Suppl 5):S93.
  • 27
    Glauber HS, Vollmer WM, Nevitt MC, Ensrud KE, Orwoll ES 1995 Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. J Clin Endocrinol Metab 80:11181123.
  • 28
    Khosla S, Atkinson EJ, Riggs BL, Melton LJ, III 1996 Relationship between body composition and bone mass in women. J Bone Miner Res 11:857863.
  • 29
    Legrand E, Chappard D, Pascaretti C, Duquenne M, Krebs S, Rohmer V, Basle MF, Audran M 2000 Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 15:1319.
  • 30
    Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM 1985 The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37:594597.
  • 31
    Mosekilde L 1998 The effect of modelling and remodelling on human vertebral body architecture. Technol Health Care 6:287297.
  • 32
    Liu G, Peacock M, Eilam O, Dorulla G, Braunstein E, Johnston CC 1997 Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int 7:564569.
  • 33
    Melton LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL 1997 Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:10831091.
  • 34
    Riggs BL, Melton LJ III, O'Fallon WM 1996 Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18:197S201S.
  • 35
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:12461254.
  • 36
    Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D 2000 Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283:13181321.